The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | Where is the field of CAR-T moving for the treatment of autoimmune diseases?
In this video, Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy, briefly discusses the future of CAR T-cell therapy for autoimmune diseases, anticipating possible approvals for certain indications in the next year. Dr Greco highlights the need for additional clinical trial data and research to confirm the encouraging results observed with CAR-T so far and to expand this therapeutic approach to a broader range of indications. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think this is really a good question. What I think we can maybe expect is, I think, to have, at least in some indication, an approval of one of the CAR T-cell approaches. Maybe not for all the indications, because not all indications are the same type of evidence, but I think that for some indications in which the numbers and the results are already more consolidated, probably with the ongoing trials that are still ongoing this year, we can expect in the next year some approval in that sense...
I think this is really a good question. What I think we can maybe expect is, I think, to have, at least in some indication, an approval of one of the CAR T-cell approaches. Maybe not for all the indications, because not all indications are the same type of evidence, but I think that for some indications in which the numbers and the results are already more consolidated, probably with the ongoing trials that are still ongoing this year, we can expect in the next year some approval in that sense. For new indications, yes, because there are ongoing trials that are going also to explore the possibility to enlarge the cohort of patients that can receive that kind of treatment. I think we need also more research in terms of target and antigen because that for sure will enlarge a little bit more, once again, the indications. And also we are moving in the field of BiTEs. So I think that in that sense, the field of autoimmunity is really going to be rapidly changing in the next years, also given all these new treatments that will be available, at least in clinical research. And we will see how many of them will be also in clinical practice in a few years from now.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
